Samit Hirawat (Bristol Myers Squibb)
After bruising rejection, bluebird and Bristol Myers Squibb land ide-cel priority review. But will it matter for the CVR?
With the clock all but up, the FDA accepted and handed priority review to Bristol Myers Squibb and bluebird bio’s BCMA CAR-T, keeping a narrow …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
